Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT ID: NCT03178071
Last Updated: 2019-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NO_LONGER_AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
NCT04127110
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
NCT03909971
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
NCT06678555
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
NCT04979988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorlatinib
oral tablets, administered daily, continuously
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Histologically or cytologically diagnosis of metastatic NSCLC that carries an ALK rearrangement or a ROS1 rearrangement
* For ALK positive patients: failure to prior treatment with at least one ALK-TKI. If prior ALK-TKI was crizotinib, additional prior treatment required with at least one second generation ALK-TKI registered and commercially available. For patients with resistance mutations not covered by other inhibitors (eg, ALK G1202R resistance mutation), prior treatment with an ALK/ROS1 inhibitor is not required.
* For ROS1 positive patients: failure to prior treatment with at least crizotinib
* Adequate bone marrow, liver, renal, pancreatic functions
* Negative pregnancy test at screening
Exclusion Criteria
* History of interstitial fibrosis or interstitial lung disease
* Concomitant use of prohibited medication
* Clinically significant cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, second degree or third degree atrioventricular block (unless paced) or any AV block with PR \>220 msec
* Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation,bradycardia, ECG with QTc \>470 msec, or congenital long QT syndrome
* History of or predisposing characteristics for acute pancreatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates, PC - NAHOA
Sedona, Arizona, United States
Pacific Shores Medical Group
Huntington Beach, California, United States
Pacific Shores Medical Group
Irvine, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
Kaiser Permanente, Oakland Medical Center
Oakland, California, United States
UC Irvine Health / Chao Family Comprehensive Cancer Center
Orange, California, United States
University of California Irvine/Chao Family Comprehensive Cancer Center
Orange, California, United States
Kaiser Permanente, South Sacramento Medical Center
Sacramento, California, United States
Kaiser Permanente, San Francisco Medical Center
San Francisco, California, United States
Kaiser Permanente, Vallejo Medical Center
Vallejo, California, United States
Memorial Cancer Institute at Memorial Hospital West
Pembroke Pines, Florida, United States
University Cancer & Blood Center, Llc
Athens, Georgia, United States
University of Chicago Medical Center, CCD
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Elmhurst Memorial Hospital Nancy W. Knowles Cancer Center
Elmhurst, Illinois, United States
Edward Cancer Center
Naperville, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute/Pharmacy
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Karmanos Cancer Institute Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri, United States
Siteman Cancer Center - West County
Creve Coeur, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Siteman Cancer Center - South County
St Louis, Missouri, United States
Rutgers Cancer Institute Of New Jersey
New Brunswick, New Jersey, United States
North Shore Hematology Oncology Associates
East Setauket, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Breast and Imaging Center - 12th floor
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
North Shore Hematology Oncology Associates
Patchogue, New York, United States
North Shore Hematology Oncology Associates
Port Jefferson Station, New York, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Ohio State University East Hospital
Columbus, Ohio, United States
The Ohio State University Investigational Drug Services
Columbus, Ohio, United States
The Ohio State University James Cancer Hospital
Columbus, Ohio, United States
The Ohio State University
Columbus, Ohio, United States
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio, United States
The Ohio State University Martha Morehouse Medical Plaza
Columbus, Ohio, United States
CarePoint Gahanna
Gahanna, Ohio, United States
UPMC Hillman Cancer Center - Patient Clinic
Pittsburgh, Pennsylvania, United States
Charleston Hematology Oncology Associates, PA
Charleston, South Carolina, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7461020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.